Impact of Patient, Surgical, and Perioperative Factors on Discharge Disposition after Radical Cystectomy

Giovanni E. Cacciamani, Ryan S. Lee, Daniel I. Sanford, Wesley Yip, Jie Cai, Gus Miranda, Siamak Daneshmand, Monish Aron, Hooman Djaladat, Inderbir S. Gill and Mihir Desai *

Impact of Patient, Surgical, and Perioperative Factors on Discharge Disposition after Radical Cystectomy

Cancers 2022, 14, 5288. https://doi.org/10.3390/cancers14215288

1. Introduction

Patient discharge disposition after surgery is a crucial aspect of perioperative care that impacts health care costs and it is listed as one of the measures of quality of care in the Center for Medicare and Medicaid Services (CMS) [1,2]. Identifying factors that predict discharge to continued facility-based rehabilitation centers (CFRs), such as skilled nursing facilities or acute rehabilitation units, may help improve perioperative protocols to facilitate surgeons’ and patients’ expectations [3] and guide proper resource allocation [4,5].

Radical cystectomy (RC) is the gold-standard surgical treatment for muscle-invasive bladder cancer [6]. RC is a complex procedure that frequently involves significant postoperative complications resulting in prolonged hospital stays and readmissions [7], placing a significant demand on the health care system [8,9]. Currently, there is limited data available on discharge disposition [10] and factors predicting discharge to CFRs after RC [11,12].
Herein, we aim to evaluate the impact of patient, surgical, and perioperative factors on discharge disposition

2. Materials and Methods

2.1. Population

Between September 2012 to March 2019, all bladder cancer patients undergoing radical cystectomy and urinary diversion with intent to cure were identified from our prospectively collected, IRB-approved institutional radical cystectomy database (HS-01B014). All procedures were performed by eight experienced surgeons. Open and robotic RC, continent (orthotopic and non-orthotopic), and incontinent urinary diversions were performed using our previously described techniques [13–19]. Baseline demographic, perioperative, and pathologic data were analyzed. Thirty- and ninety-day postoperative complications were classified according to the modified Clavien–Dindo classification [20]. Readmission was defined as any subsequent inpatient admission or unplanned visit occurring within 30 or 90 days from the day of discharge [7]. Post-operatively, the patients were managed per our institutional Enhanced Recovery After Surgery (ERAS) protocol as described previously [21] with some surgeon-specific differences [22]. Patients were recommended discharge to either home or to a CFR based on detailed physical and occupational therapy evaluation.

2.2. Statistical Analysis

Patients were distributed into 2 groups based on discharge disposition after RC: to home with home health services) or to CFRs, which include skilled nursing facilities, acute rehabilitation units, and transitional care units.

A univariate analysis was performed to compare baseline differences in demographics, surgical factors, and perioperative outcomes between the two groups. Continuous and categorical variables were presented as mean and standard deviation (SD), and median and interquartile range (IQR), respectively. In the univariate analysis, Kruskal-Wallis, chi-squared ($X^2$), and Fisher exact tests were used to compare continuous and categorical variables as appropriate. We then performed separate multivariable logistic regression models. The travel distance was determined by measuring the straight-line distance (in miles) between the patient’s residence ZIP code/postal code and the treatment institution’s ZIP code/postal code (ZIPDISTANCE FUNCTION; SAS software, version 9.2; SAS Institute Inc., Cary, NC, USA)

With our predictive model analysis, we sought to identify independent factors associated with our main outcome of interest: discharge to CFRs. The multivariable model included variables previously found to be predictors of discharge to CFR and significant variables from our preliminary univariate analysis. Patient characteristics included in the multivariable model were age, gender, body mass index (BMI), race, ASA score, Charlson Comorbidity Index (CCI), smoking habits, marital status, living situation before surgery, type of primary health insurance, and neoadjuvant chemotherapy (NACH). Surgical and perioperative variables included in the multivariable model were ERAS protocol, surgical approach (open or robot-assisted), type of urinary diversion, and occurrence of in-hospital complications.

A two-tailed test with $p < 0.05$ was considered statistically significant. All statistical analyses were performed using SPSS v.24.0 (SPSS Inc., Chicago, IL, USA). Data and methods were reported according to the most recent guidelines for reporting statistics for clinical research in urology [23].

3. Results

3.1. Baseline Demographics

A total of 1153 patients were included in this study. Demographic data are detailed in Table 1. Median (IQR) age was 71.0 (63.0–77.0) years and BMI was 26.9 (23.7–30.3) kg/m$^2$. A total of 928 (80.49%) patients were male, 938 (81.42%) patients had ASA score of III or IV, 361 (31.31%) patients received neoadjuvant chemotherapy, and 395 (34.26%) patients
presented with pT ≥ 3 disease. In our cohort, 836 (72.51%) patients were married and 220 (19.25%) lived alone prior to surgery. Most patients (58.63%) in our cohort had government (i.e., Medicare, Tricare) insurance. A detailed description of insurance types is demonstrated in Table 1.

Table 1. Perioperative characteristics.

| Patients, n (%) | Total | Home (with Home Care) | Continued Facility-Based Rehabilitation Centers | p-Value |
|----------------|-------|-----------------------|-----------------------------------------------|---------|
| Age, yrs., mean (SD)/median (IQR) | 70.0 (10.5)/71.0 (63.0–77.0) | 68.9 (10.4)/70.0 (62.0–76.0) | 75.8 (9.0)/76.0 (71.0–82.0) | <0.001 |
| BMI, Kg/m², mean (SD)/median (IQR) | 27.4 (5.2)/26.9 (23.7–30.3) | 27.4 (5.0)/26.9 (23.9–30.3) | 27.0(5.9)/26.6 (22.1–30.8) | 0.17 |
| Gender | | | | |
| Male, n (%) | 928 (80.49%) | 801 (82.32%) | 127 (70.56%) | <0.001 |
| Female, n (%) | 225 (19.51%) | 172 (17.68%) | 53 (29.44%) | |
| ASA score, mean (SD)/median (IQR) | | | | 0.005 |
| ASA 1–2, n (%) | 214 (18.58%) | 194 (19.94%) | 20 (11.74%) | |
| ASA 3–4, n (%) | 938 (81.42%) | 779 (80.06%) | 159 (88.83%) | |
| CCI, mean (SD)/Median (IQR) | 1.4 (1.5)/1.0 (0.0–2.0) | 1.3 (1.5)/1.0 (0.0–1.0) | 1.7 (1.6)/1.0 (0.0–3.0) | 0.001 |
| CCI 0, n (%) | 434 (37.6%) | 385 (39.61%) | 49 (27.22%) | 0.005 |
| CCI 1, n (%) | 260 (22.57%) | 216 (22.22%) | 44 (24.44%) | |
| CCI ≥2, n (%) | 458 (39.76%) | 371 (38.17%) | 87 (48.33%) | |
| Smoking Status | | | | 0.79 |
| Ever | 811 (70.34%) | 686 (70.50%) | 125 (69.44%) | |
| Never | 342 (29.66%) | 237 (29/50%) | 55 (30.56%) | |
| Preoperative Albumin mean (SD)/Median (IQR) | 26.1 (20.0)/38.0 (0.0–42.0) | 26.3 (20.1)/39.0 (0.0–42.0) | 25.1 (19.5)/37.0 (0.0–41.0) | 0.05 |
| Diabetes, n (%) | 253 (21.96%) | 207 (21.30%) | 46 (25.56%) | 0.2 |
| Pulmonary comorbidity n (%) | 185 (16.06%) | 146 (15.02%) | 39 (21.67%) | 0.035 |
| Cardiac comorbidity n (%) | 24 (2.08%) | 18 (1.85%) | 6 (3.33%) | 0.25 |
| Renal comorbidity n (%) | 132 (11.46%) | 106 (10.91%) | 26 (14.44%) | 0.2 |
| Baseline Hgb, mean (SD)/Median (IQR) | 12.0 (2.9)/12.0(10.2–13.6) | 12.1 (3.0)/12.0 (10.3–13.7) | 11.6 (2.0)/11.8 (9.9–13.1) | 0.04 |
| Baseline Creatinine, mean, (SD)/Median (IQR) | 1.2 (0.7)/1.1 (0.9–1.4) | 1.2 (0.7)/1.1 (0.9–1.4) | 1.2 (0.6)/1.0 (0.9–1.4) | 0.05 |
| NACH, n (%) | 361 (31.31%) | 316 (32.48%) | 45 (24.00%) | 0.054 |
| Marital Status | | | | <0.001 |
| Married, n (%) | 836 (72.51%) | 766 (78.73%) | 70 (38.89%) | |
| Single/Widowed, n (%) | 317 (27.49%) | 207 (21.27%) | 110 (61.1%) | |
| Living status Before Surgery | | | | <0.001 |
| Alone, n (%) | 220 (19.25%) | 133 (13.78%) | 87 (48.88%) | |
| Not Alone, n (%) | 923 (80.75%) | 832 (86.22%) | 91 (51.12%) | |
### Table 1. Cont.

| Living status After Surgery | Total | Home (with Home Care) | Continued Facility-Based Rehabilitation Centers | \(p\)-Value |
|-----------------------------|-------|-----------------------|-----------------------------------------------|-------------|
| Alone, \(n\) (%)           | 234 (20.58%) | 81 (8.46%)            | 153 (85.47%)                                  | <0.001      |
| Not Alone, \(n\) (%)       | 903 (79.42%) | 877 (91.54%)          | 26 (14.53%)                                   |             |

| Race                        |       |                       |                                               |             |
|-----------------------------|-------|-----------------------|-----------------------------------------------|-------------|
| White American, \(n\) (%)  | 955 (82.83%) | 800 (82.22%)          | 155 (86.11%)                                  | 0.24        |
| Non-White American, \(n\) (%) | 198 (17.7%) | 173 (17.78%)          | 25 (13.89%)                                   |             |

| Insurance type              |       |                       |                                               |             |
|-----------------------------|-------|-----------------------|-----------------------------------------------|-------------|
| Private (includes PPO, LOA, commercial), \(n\) (%) | 204 (17.69%) | 171 (17.57%)          | 33 (18.33%)                                   |             |
| HMO, \(n\) (%)              | 217 (18.82%) | 201 (20.66%)          | 16 (8.89%)                                    |             |
| Government (includes Medicare, Tricare) | 676 (58.63%) | 553 (56.83%)          | 123 (68.33%)                                  | 0.01        |
| Medi-Cal, \(n\) (%)         | 19 (1.65%)       | 17 (1.75%)            | 2 (1.11%)                                     |             |
| Cash, \(n\) (%)             | 19 (1.65%)       | 16 (1.64%)            | 3 (1.67%)                                     |             |
| Miscellaneous, \(n\) (%)    | 18 (1.56%)       | 15 (1.54%)            | 3 (1.67%)                                     |             |

| Pathologic Tumor Stage      |       |                       |                                               |             |
|-----------------------------|-------|-----------------------|-----------------------------------------------|-------------|
| \(pT \leq 2\)               |       |                       |                                               |             |
| \(pT0, n\) (%)              | 190 (16.48%) | 169 (17.37%)          | 21 (11.67%)                                   |             |
| \(pT1S, n\) (%)             | 171 (14.83%) | 146 (15.01%)          | 25 (13.89%)                                   |             |
| \(pTa, n\) (%)              | 39 (3.38%)       | 34 (3.49%)            | 5 (2.78%)                                     |             |
| \(pT1, n\) (%)              | 148 (12.84%) | 130 (13.36%)          | 18 (10.00%)                                   |             |
| \(pT2a, n\) (%)             | 103 (8.93%) | 89 (9.15%)            | 14 (7.78%)                                    | 0.14        |
| \(pT2b, n\) (%)             | 107 (9.28%) | 89 (9.15%)            | 18 (10.00%)                                   |             |
| \(pT \geq 3\)               |       |                       |                                               |             |
| \(pT3a, n\) (%)             | 170 (14.74%) | 138 (14.18%)          | 32 (17.78%)                                   |             |
| \(pT3b, n\) (%)             | 105 (9.11%) | 79 (8.12%)            | 26 (14.44%)                                   |             |
| \(pT4a, n\) (%)             | 116 (10.06%) | 96 (9.87%)            | 20 (11.11%)                                   |             |
| \(pT4b, n\) (%)             | 4 (0.35%)       | 3 (0.31%)             | 1 (0.56%)                                     |             |

| pNstage                     |       |                       |                                               |             |
|-----------------------------|-------|-----------------------|-----------------------------------------------|-------------|
| \(pN0, n\) (%)             | 896 (77.71%) | 761 (78.21%)          | 135 (75.00%)                                  |             |
| \(pN1, n\) (%)             | 77 (6.68%) | 65 (6.68%)            | 12 (6.67%)                                    |             |
| \(pN2, n\) (%)             | 158 (13.70%) | 130 (13.36%)          | 28 (15.56%)                                   |             |
| \(pN3, n\) (%)             | 5 (0.43%)       | 5 (0.51%)             | 0                                             | 0.06        |
| \(pNx, n\) (%)             | 17 (1.47%)       | 12 (1.23%)            | 5 (2.78%)                                     |             |

| pM stage                    |       |                       |                                               |             |
|-----------------------------|-------|-----------------------|-----------------------------------------------|-------------|
| \(pM0, n\) (%)             | 1153 (100.0%) | 973 (100%)            | 180 (100%)                                    | 1           |

#### 3.2. Perioperative Outcomes

Perioperative outcomes are detailed in Table 2. 763 (66.18%) patients underwent open radical cystectomy compared to 390 (33.82%) patients who underwent robot-assisted radical cystectomy. The mean (SD) operative time was 6.0 (1.7) hours. Orthotopic neobladder and an incontinent urinary diversion were performed in 587 (50.91%) and 527 (45.71%) patients,
respectively. Median (IQR) intraoperative estimated blood loss (EBL) was 400 (200–400) mL, and 220 (19.08%) patients required perioperative blood transfusions. 381 (33.10%) and 98 (8.51%) patients experienced minor (Clavien I-II) and major (Clavien III-IV) complications during their hospital course, respectively. Mean (SD) length of stay was 6.3 (5.0) days, and 90-day readmission and mortality were seen in 354 (30.70%) and 53 (4.60%) patients, respectively.

Table 2. Surgical and Perioperative outcomes.

| Patients, n (%) | Total | Home (with Home Care) | Continued Facility-Based Rehabilitation Centers | \( p \)-Value |
|----------------|-------|-----------------------|------------------------------------------------|-----------|
| \( p \)-Value | 1153  | 973 (84.39%)          | 180 (15.61%)                                   | 0.37      |
| Enhanced recovery after surgery setting |       |                       |                                                |           |
| ERAS, n (%) | 830 (89.63%) | 705 (90.04%) | 125 (87.41%) | 0.37 |
| Non-ERAS, n (%) | 96 (10.37%) | 78 (9.96%) | 18 (12.59%) | 0.37 |
| Not reported, n (%) | 227 | 190 | 37 | 0.37 |
| Surgical Approach |       |                       |                                                |           |
| Robotic, n (%) | 390 (33.82%) | 328 (33.71%) | 62 (34.44%) | 0.864 |
| Open, n (%) | 763 (66.18%) | 645 (66.29%) | 118 (65.56%) | 0.864 |
| Type of Urinary Diversion |       |                       |                                                |           |
| Incontinent, n (%) | 527 (45.71%) | 416 (42.75%) | 111 (61.67%) | <0.001 |
| Continent-non-orthotopic, n (%) | 39 (3.38%) | 32 (3.29%) | 7 (3.89%) | 0.37 |
| Continent-orthotopic, n (%) | 587 (50.91%) | 525 (53.96%) | 62 (34.44%) | 0.37 |
| Operative Time, hours (SD)/median (IQR) | 6.0 (1.7)/5.9 (4.8–7.1) | 6.1 (1.7)/4.9 (4.8–7.1) | 6.0 (1.7)/5.7 (4.8–7.0) | 0.36 |
| EBLs, ml (SD)/median (IQR) | 400.0 (200.0–600.0) | 459.1 (354.4)/375.0 (200.0–600.0) | 533.4 (832.6)/400 (250.0–600.0) | 0.44 |
| Perioperative Transfusions, n (%) | 220 (19.08%) | 174 (17.88%) | 46 (25.56%) | 0.023 |
| Postoperative transfusions, n (%) | 240 (20.82%) | 186 (19.12%) | 54 (30.00%) | 0.001 |
| Perioperative complications |       |                       |                                                |           |
| In-hospital Complication (within hospital stay) |       |                       |                                                |           |
| No complications | 672 (58.38%) | 594 (61.17%) | 78 (43.33%) | <0.001 |
| Minor, n (%) | 381 (33.10%) | 310 (31.93%) | 71 (39.44%) | <0.001 |
| Major, n (%) | 98 (8.51%) | 67 (6.90%) | 31 (17.22%) | <0.001 |
| Transfusion n (%) | 380 (32.96%) | 299 (30.73%) | 81 (45.00%) | <0.001 |
| Cardiac system n, (%) | 128 (11.10%) | 97 (9.97%) | 31 (17.22%) | 0.007 |
| Pulmonary system n, (%) | 39 (3.38%) | 22 (2.26%) | 17 (9.44%) | <0.001 |
| Gastrointestinal system n, (%) | 326 (28.27%) | 269 (27.65%) | 57 (31.67%) | 0.28 |
| Uro-Genital system, n (%) | 269 (23.33%) | 227 (23.33%) | 42 (23.33%) | 1 |
| Neuronal System n, (%) | 62 (5.38%) | 53 (5.45%) | 9 (5.00%) | 1 |
| Infections, n (%) | 376 (32.61%) | 299 (30.73%) | 77 (42.78%) | 0.002 |
| Overall, 30 days complications, n (%) | 705 (61.14%) | 568 (58.38%) | 137 (76.11%) | <0.001 |
| Minor, n (%) | 548 (47.53%) | 451 (46.35%) | 97 (53.89%) | <0.001 |
| Major, n (%) | 154 (13.36%) | 114 (1.72%) | 40 (22.22%) | <0.001 |
3.3. Discharge Disposition

Figure 1 depicts the annual distribution of discharge dispositions. A total of 180 (15.61%) patients were discharged to CFRs. On univariate analysis of patient characteristics, age (68.0 vs. 75.8 years, \( p < 0.001 \)), gender (13.69% of males vs 23.56% of females, \( p < 0.001 \)), ASA (\( p = 0.005 \)), CCI (\( p = 0.002 \)), preoperative albumin level (26.3 vs. 25.1 g/dL, \( p = 0.05 \)), baseline hemoglobin (12.1 vs. 11.6 g/dL, \( p = 0.04 \)), baseline creatinine (1.2 vs 1.2 mg/dL, \( p = 0.05 \)), marital status (\( p < 0.001 \)), living alone before surgery (\( p < 0.001 \)), living alone after surgery (\( p < 0.001 \)), and insurance type (\( p = 0.01 \)) were significantly different in patients discharged home compared to patients discharged to CFRs. On univariate analysis of perioperative variables, urinary diversion type (\( p < 0.001 \)), perioperative (\( p = 0.023 \)) and post-operative (\( p = 0.001 \)) transfusions, complications during the hospital course (\( p < 0.001 \)), and hospital length of stay (LOS) (5.8 vs. 7.0 days, \( p < 0.001 \)) were significantly different. Mortality rate at 30 days (0.72% vs 2.78%, \( p = 0.027 \)) and 90 days (2.88% vs. 13.89%, \( p < 0.001 \)) as well as readmission rate at 30 days (17.99% vs 25.00%, \( p = 0.03 \)) and 90 days (24.63% vs. 38.89%, \( p = 0.011 \)) were also significantly different between the two groups. Of note, no significant difference was seen in the distance traveled for care between the two groups (\( p = 0.89 \)).

Multivariate analysis of combined patient, surgical and perioperative factors (Figure 2) indicated that age (RR: 1.09, \( p < 0.001 \)), single marital status (RR: 3.9, \( p < 0.001 \)), living alone prior to surgery (RR: 2.42, \( p = 0.01 \)) and major complications during the hospital course (RR: 3.44, \( p < 0.001 \)) were significant predictors of discharge to CFRs. Surgical approach and type of urinary diversion were no longer significant risk factors when assessing patient and surgical factors on multivariate analysis.
Figure 1. Trend over time of RC performed in our institution (2012–2019) after the implementation of our ERAS protocol and percentage of patients discharged home and to CFRs.

Figure 2. Multivariable regression models assessing the impact of patient, surgical, and perioperative factors on discharge disposition after RC. Patients without ERAS information were excluded from further analysis. RR: Risk Ratio; CI: Confidence Interval; CCI: Charlson Comorbidity Index; BMI: body mass index; LOS: length of stay; NACH: Neoadjuvant Chemotherapy; ERAS: Enhanced Recovery After Surgery; CFR: Continued Facilities-based Rehabilitation Center.

4. Discussion

The last decade has brought several changes in the perioperative management of RC patients, especially with the incorporation of ERAS protocols, which have been shown...
to reduce hospital length of hospital stay, time to first flatus, and time to resumption of a regular diet [24–26]. ERAS protocols are also associated with improved quality-of-life measures during the recovery process and a decrease in overall costs [27]. Complication and readmission rates at 90 days after surgery, however, have not significantly changed with ERAS protocols [28]. While an abundance of research has evaluated perioperative management of radical cystectomy patients, there remains a paucity of modern data with conflicting results regarding patient discharge disposition [10–12,29].

Discharge to CFRs after a major abdominopelvic surgery is associated with a worse prognosis and overall survival [30]. Moreover, readmissions from these facilities are common, costly, and often avoidable. Approximately 23.5% of Medicare beneficiaries are readmitted to a hospital within 30 days of discharge to a skilled nursing facility, and 78% of these readmissions are potentially avoidable [31]. Taub et al. first reported the increasing proportion of discharge to subacute care facilities after cystectomy using data from the Nationwide Inpatient Sample. From 1988 to 2000, discharge to CFRs increased from 5.3 to 13.2% [10]. In a retrospective review of a single-institution series of 445 patients from 2004 to 2007, the main factors associated with discharge to a CFR after RC were older age, lower preoperative fitness level, and longer length of stay. Of note, in our cohort, patients discharged to a CFR had a higher mortality rate within 90-days of surgery (13.89% vs. 2.88%) [12]. Several factors have been identified as predictors of discharge to CFRs after cystectomy, including frailty, skeletal mass, and fat mass [11,29].

A better understanding of predictors of discharge to CFRs, specifically those that are modifiable, could help guide preoperative counseling and discharge planning. Our analysis of 1153 patients undergoing RC for bladder cancer in a tertiary referral center suggests that several patients and perioperative factors significantly impact discharge disposition. Importantly, we also found that patients discharged to CFRs had 90-day readmission and mortality rates similar to the rates reported by Aghazadeh et al. [12].

We found age to be a significant factor for discharge to a CFR. However, age is a non-modifiable factor that will likely continue to impact discharge disposition as most patients diagnosed with and undergoing RC for bladder cancer are older [32–34] with an average age of 73 years at diagnosis [35]. Care for the post-cystectomy patient can be complex and requires additional support at home [36]. In a qualitative study of bladder cancer patient experiences, patients valued support from friends and family, especially when learning new techniques such as catheterization [37]. Thus, it is not surprising that patients who are not married and/or living alone are more likely to be discharged to a CFR. Similarly, elderly patients living alone prior to both emergent and elective abdominal procedures are more likely to be discharged to subacute facilities [38,39]. In contrast to a study of 6460 RC patients in the Premier Perspectives Database by Nayak et al., comorbidities were not a predictor of discharge to CFRs in our analysis [40]. Thus, our association of age and discharge disposition may be more related to functional and performance status, such as frailty, rather than medical complexity. It has been reported that tobacco smoking impacts perioperative complications [41] and overall survival [42] after RC, but its impact on discharge disposition has not yet been evaluated. Our results did not find an association between smoking habits and discharge disposition after RC. The patient-specific results of our study can potentially guide preoperative counseling to manage expectations and to start discharge planning early (as part of our ERAS protocol this is conducted on POD1).

Of the surgery and perioperative factors that were significant in our analysis, patients undergoing non-orthotopic diversions were more likely to be discharged to a CFR. In our cohort, 89.44% of patients undergoing neobladder formation were discharged home. Although an open approach was associated with discharge to CFRs on univariate analysis, it is confounded by the fact that patients undergoing an open procedure were often older than those undergoing robotic surgery. The median length of stay in our cohort was 5 days, and patients with prolonged length of stay (>5 days) were more likely to be discharged to a CFR. This could be associated with non-medical factors causing prolonged hospitalization, such as locating a CFR. Lastly, patients who experienced major complications (Clavien
III–IV) during their admission were also more frequently discharged to a facility, which is likely related to their overall complexity of care and recovery from complications. Our prior work has found that intraoperative transfusions were associated with 30-day complication rates in patients undergoing radical cystectomy with an ERAS protocol [43]. As such, reduction in major perioperative complications may be the only potential modifiable factor in discharge disposition and should remain a top focus of ERAS protocols.

Even though our study suggests that most factors that affect discharge disposition may not be modifiable, this information is useful in optimizing care even in patients who are likely to be discharged to CFR’s. ERAS protocols [44–46] should include a pre-operative checklist that determines the likelihood of discharge to a CFR pre-operatively so that the appropriate facility can be assigned to minimize unnecessarily prolonged hospital stays. CFR’s should be educated with the specific needs and early complication identification of radical cystectomy patients to reduce the probability of readmission from these facilities.

Our study has several limitations. Although our bladder cancer database is prospectively maintained, this study was a retrospective review and analysis. The analysis included patients who underwent RC through different approaches (open and robotic), and only one surgeon at our institution routinely performs both. Moreover, as demonstrated in a previously published internal audit from our institution, patients undergoing open RC were more compliant with ERAS protocol than those undergoing robotic RC [22]. Lastly, several confounding factors that were significant predictors of discharge disposition in other studies, such as frailty and performance status, were not available for inclusion in our analysis.

5. Conclusions

Patient and perioperative factors impact discharge disposition after radical cystectomy for bladder cancer. Our results suggest that predictors of discharge to CFRs seem to be nonmodifiable and can be identified prior to surgery (i.e., age, marital status, living situation) except for the presence of major complications during the post-operative hospital course. Thus, recognizing these nonmodifiable patient factors preoperatively can help identify which patients may require discharge to a CFR. By providing proper patient education, both patients and urologists can better plan for the postoperative course and anticipate discharge expectations and needs appropriately.

Author Contributions: Conceptualization, G.E.C., R.S.L., S.D., M.A., H.D., I.S.G. and M.D.; methodology, G.E.C., R.S.L., J.C., G.M. and M.D.; software, J.C. and G.M.; formal analysis, J.C. and G.M.; writing—original draft preparation, G.E.C., R.S.L., J.C., G.M. and M.D.; writing—review and editing, G.E.C., R.S.L., D.I.S., W.Y., S.D., M.A., H.D., I.S.G. and M.D. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of University of Southern California (HS-01B014).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available to maintain HIPAA Compliance.

Conflicts of Interest: Inderbir Gill is unpaid an advisor for Steba Biotech. Siamak Daneshmand is a consultant for Janssen, Ferring, Photocure, Taris, Spectrum, Pacific Edge, QED, Abbvie, Johnson & Johnson, Seattle Genetics, Nucleix, Aduro, and BMS. Mihir Desai is a consultant for Procept Biorobotics and Auris Surgical.
References

1. Costantino, M.E.; Frey, B.; Hall, B.; Painter, P. The Influence of a Postdischarge Intervention on Reducing Hospital Readmissions in a Medicare Population. *Popul. Health Manag.* 2013, 16, 310–316. [CrossRef] [PubMed]

2. The Centers for Medicare & Medicaid Services (CMS). Available online: https://www.cms.gov (accessed on 1 September 2021).

3. Stuebe, J.; Rydingsward, J.; Lander, H.; Ng, J.; Xu, X.; Kaneko, T.; Shekar, P.; Muehlschlegel, J.D.; Body, S.C. A Pragmatic Preoperative Prediction Score for Nonhome Discharge After Cardiac Operations. *Ann. Thorac. Surg.* 2018, 105, 1384–1391. [CrossRef] [PubMed]

4. Kumar, R.A.; Asanad, K.; Miranda, G.; Cai, J.; Djaladat, H.; Ghodoussipour, S.; Desai, M.M.; Gill, I.S.; Cacciamani, G.E. Population-Based Assessment of Determining Predictors for Discharge Disposition in Patients with Bladder Cancer Undergoing Radical Cystectomy. *Cancers* 2022, 14, 4613. [CrossRef]

5. Ahn, A.; Phan, K.; Cheung, Z.B.; White, S.J.; Kim, J.S.; Cho, S.K.W. Predictors of Discharge Disposition Following Laparotomy for Intradural Extramedullary Spinal Tumors. *World Neurosurg.* 2019, 123, e427–e432. [CrossRef] [PubMed]

6. Witjes, J.A.; Bruins, H.M.; Cathomas, R.; Compérat, E.M.; Cowan, N.C.; Gakis, G.; Hernández, V.; Espinós, E.L.; Lorch, A.; Neuzillet, Y.; et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. *Eur. Urol.* 2020, 79, 82–104. [CrossRef] [PubMed]

7. Cacciamani, G.E.; Medina, L.; Lin-Brande, M.; Tafuri, A.; Lee, R.S.; Ghodoussipour, S.; Ashrafi, A.N.; Winter, M.; Ahmadi, N.; Rajarubendra, N.; et al. Timing, Patterns and Predictors of 90-days Readmission Rate after Robotic Radical Cystectomy. *J. Urol.* 2021, 205, 491–499. [CrossRef]

8. Leow, J.J.; Cole, A.P.; Seisen, T.; Bellmunt, J.; Mossanen, M.; Menon, M.; Preston, M.A.; Choueiri, T.K.; Kibel, A.S.; Chung, B.I.; et al. Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. *Eur. Urol.* 2018, 73, 374–382. [CrossRef]

9. Sloan, F.A.; Yashkin, A.P.; Akushevich, I.; Inman, B. The Cost to Medicare of Bladder Cancer Care. *Eur. Urol. Oncol.* 2020, 3, 515–522. [CrossRef]

10. Taub, D.A.; Dunn, R.L.; Miller, D.C.; Wei, J.T.; Hollenbeck, B.K. Discharge Practice Patterns Following Cystectomy for Bladder Cancer: Evidence for the Shifting of the Burden of Care. *J. Urol.* 2006, 176 Pt 1, 2612–2618, discussion 2617–2618. [CrossRef]

11. Allbersheim, J.; Sathianathen, N.J.; Zabell, J.; Renier, J.; Bailey, T.; Hanna, P.; Konety, B.R.; Weight, C.J. Skeletal Muscle and Fat Mass Indexes Predict Discharge Disposition After Radical Cystectomy. *J. Urol.* 2019, 202, 1143–1149. [CrossRef]

12. Aghazadeh, M.A.; Barocas, D.A.; Salem, S.; Clark, P.E.; Cookson, M.S.; Davis, R.; Gregg, J.; Stimson, C.; Smith, J.A.; Chang, S.S. Determining Factors for Hospital Discharge Status After Radical Cystectomy in a Large Contemporary Cohort. *J. Urol.* 2011, 185, 85–89. [CrossRef] [PubMed]

13. Desai, M.M.; Simone, G.; Abreu, A.L.D.C.; Chopra, S.; Ferriero, M.; Guagianione, S.; Minisola, F.; Park, D.; Sotelo, R.; Gallucci, M.; et al. Robotic Intracorporeal Continent Cystourethral Diversion. *J. Urol.* 2017, 198, 436–444. [CrossRef] [PubMed]

14. Abreu, A.L.d.C.; Chopra, S.; Azhar, R.A.; Berger, A.K.; Miranda, G.; Cai, J.; Gill, I.S.; Aron, M.; Desai, M.M. Robotic radical cystectomy and intracorporeal urinary diversion: The USC technique. *Indian J. Urol.* 2014, 30, 300–306. [PubMed]

15. Cacciamani, G.E.; Rajarubendra, N.; Artibani, W.; Gill, I.S. Robotic intracorporeal urinary diversion: State of the art. *Curr. Opin. Urol.* 2019, 29, 293–300. [CrossRef]

16. Cacciamani, G.E.; Winter, M.; Medina, L.G.; Ashrafi, A.N.; Miranda, G.; Tafuri, A.; Landsberger, H.; Lin-Brande, M.; Rajarubendra, N.; Abreu, A.D.C.; et al. Radical cystectomy pentafecta: A proposal for standardisation of outcomes reporting following robot-assisted radical cystectomy. *Br. J. Urol.* 2019, 125, 64–72. [CrossRef]

17. Medina, L.G.; Baccaglini, W.; Hernández, A.; Rajarubendra, N.; Winter, M.; Ashrafi, A.N.; Tafuri, A.; Cacciamani, G.E.; Sotelo, R. Robotic intracorporeal ileal conduit: Technical aspects. *Arch. Esp. Urol.* 2019, 72, 299–308.

18. Stein, J.P.; Skinner, D.G. Surgical atlas. Radical cystectomy. *BJU Int.* 2004, 94, 197–221. [CrossRef]

19. Cacciamani, G.E.; Shakir, A.; Tafuri, A.; Gill, K.; Han, J.; Ahmadi, N.; Hubeer, P.A.; Gallucci, M.; Simone, G.; Campi, R.; et al. Best practices in near-infrared fluorescence imaging with indocyanine green (NIRF/ICG)-guided robotic urologic surgery: A systematic review-based expert consensus. *World J. Urol.* 2019, 38, 883–896. [CrossRef]

20. Dindo, D.; Demartines, N.; Clavien, P.A. Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey. *Ann. Surg.* 2004, 240, 205–213. [CrossRef]

21. Daneshmand, S.; Ahmadi, H.; Schuckman, A.K.; Mitra, A.P.; Cai, J.; Miranda, G.; Djaladat, H. Enhanced Recovery Protocol after Radical Cystectomy for Bladder Cancer. *J. Urol.* 2014, 192, 50–56. [CrossRef]

22. Ghodoussipour, S.; Naser-Tavakolian, A.; Cameron, B.; Mitra, A.P.; Miranda, G.; Cai, J.; Bhanvadia, S.; Aron, M.; Desai, M.; Gill, I.; et al. Internal audit of an enhanced recovery after surgery protocol for radical cystectomy. *World J. Urol.* 2020, 38, 3131–3137. [CrossRef] [PubMed]

23. Assel, M.; Sjöberg, D.; Elders, A.; Wang, X.; Huo, D.; Botchway, A.; Delfino, K.; Fan, Y.; Zhao, Z.; Koyama, T.; et al. Guidelines for Reporting of Statistics for Clinical Research in Urology. *J. Urol.* 2019, 201, 595–604. [CrossRef] [PubMed]

24. Zhang, D.; Sun, K.; Wang, T.; Wu, G.; Wang, J.; Cui, Y.; Wu, J. Systematic Review and Meta-Analysis of the Efficacy and Safety of Enhanced Recovery After Surgery vs. Conventional Recovery After Surgery on Perioperative Outcomes of Radical Cystectomy. *Front. Oncol.* 2020, 10, 541390. [CrossRef] [PubMed]

25. Giannarini, G.; Crestani, A.; Inferrera, A.; Rossanesi, M.; Subba, E.; Novara, G.; Ficarra, V. Impact of enhanced recovery after surgery protocols versus standard of care on perioperative outcomes of radical cystectomy: A systematic review and meta-analysis of comparative studies. *Minerva Urol. Nefrol.* 2019, 71, 309–323. [CrossRef]
